 "Cadila Healthcare hits new high on USFDA approval for new drug")
Cadila Healthcare rallied 10% to Rs 539, also its new high on BSE in intra-day trade, after Zydus Cadila said the US Food and Drug Administration (USFDA) has given the final approval to market the company’s Mesalamine Delayed-Release tablets USP, 1.2 g in the US market.
Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda (Mesalamine).
“Lialda is indicated for the treatment of mild to moderate ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects approximately 700,000 people in the United States,” the company said in a press release.
The generic version of Lialda (Mesalamine), will be produced at the company’s Moraiya plant located at Ahmedabad.
As per IMS MAT April 2017, the estimated brand sales for Mesalamine delayed-release tablets USP, 1.2 g is US$ 1.145 billion.
In past nine trading sessions, the stock of Cadila Healthcare has outperformed the market by surging 26% as compared to 1.8% rise in the S&P BSE Sensex.
At 10:06 am; it was up 9% to Rs 534 against 0.33% rise in the benchmark index. The trading volumes on the counter jumped nearly four-fold with a combined 5.57 million shares changed hands on the BSE and NSE so far.
Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda (Mesalamine).
“Lialda is indicated for the treatment of mild to moderate ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects approximately 700,000 people in the United States,” the company said in a press release.
The generic version of Lialda (Mesalamine), will be produced at the company’s Moraiya plant located at Ahmedabad.
As per IMS MAT April 2017, the estimated brand sales for Mesalamine delayed-release tablets USP, 1.2 g is US$ 1.145 billion.
In past nine trading sessions, the stock of Cadila Healthcare has outperformed the market by surging 26% as compared to 1.8% rise in the S&P BSE Sensex.
At 10:06 am; it was up 9% to Rs 534 against 0.33% rise in the benchmark index. The trading volumes on the counter jumped nearly four-fold with a combined 5.57 million shares changed hands on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%